Biomarker Identification for anti-VEGF Resistance in Exudative AMD
- Investigator Initiated
- Principal Investigator: Barbara Blodi, MD
- Study Coordinator: Bonnie Verges
Study objective:
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.
Study design:
One study visit involving collection of a blood sample for genetic/DNA analysis.
Inclusion criteria:
- Male or female patients ˃ 50 years of age with diagnosis of age-related macular degeneration in both eyes
- Patients with exudative age-related macular degeneration in at least one eye undergoing regular treatment with one or more anti-VEGF agents in the past year. Regular treatment would be 4 or more injections per year.
Exclusion criteria:
- Presence of atrophy or fibrosis under the center of the macula